Literature DB >> 19247576

Interstitial lung disease in polymyositis and dermatomyositis.

I-Jung Chen1, Yeong-Jian Jan Wu, Cho-Wei Lin, Kang-Wei Fan, Shue-Fen Luo, Huei-Huang Ho, Lieh-Bang Liou, Wen-Pin Tsai, Ji-Yih Chen, Chung-Han Yang, Chang-Fu Kuo, Kuang-Hui Yu.   

Abstract

The aim of the study was to estimate the prevalence, characteristics, and prognostic factors of interstitial lung disease (ILD) in patients with polymyositis (PM) and dermatomyositis (DM). The medical records of 151 PM/DM patients treated at Chang Gung Memorial Hospital between January, 2000 and June, 2007 were retrospectively reviewed. Thirty of 151 (19.9%) PM/DM patients had developed ILD. Older age at PM/DM onset, anti-Jo-1 antibody, and arthritis/arthralgia were associated with the presence of ILD (p = 0.004, p = 0.008, and p = 0.026, respectively). Anti-Jo-1 was initially excluded from the multivariate analysis because only 80 patients underwent the test. An older age at onset above 45 years (odds ratio 3.28, 95% confidence interval (CI) 1.15-9.34, p = 0.026) and arthritis/arthralgia at onset (odds ratio (OR) 2.57, 95% CI 1.09-6.08, p = 0.032) were the two independent risk factors for developing ILD. If anti-Jo-1 was included in the multivariate analysis (n = 80), then an older age at onset above 45 years (OR 7.30, 95% CI 1.70-31.40, p = 0.008) and anti-Jo-1 positive (OR 7.89, 95% CI 1.18-52.87, p = 0.033) were associated with ILD, while arthritis/arthralgia was no longer significant (OR 2.64, 95% CI 0.70-10.01, p = 0.153). Of the 30 ILD patients, 16 (53.3%) died. The survival time was significantly shorter in ILD patients than in patients without ILD (p < 0.001). Poor survival in ILD patients was associated with male gender (p = 0.039), a Hamman-Rich-like presentation (p = 0.039), and a clinical diagnosis of acute interstitial pneumonia (p = 0.007).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19247576     DOI: 10.1007/s10067-009-1110-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  33 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Interstitial lung disease related to dermatomyositis. Comparative study with patients without lung involvement.

Authors:  J M Grau; O Miró; E Pedrol; J Casademont; F Masanés; C Herrero; G Haussman; A Urbano-Márquez
Journal:  J Rheumatol       Date:  1996-11       Impact factor: 4.666

3.  Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study.

Authors:  Y J Chen; C Y Wu; J L Shen
Journal:  Br J Dermatol       Date:  2001-04       Impact factor: 9.302

4.  Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine.

Authors:  Y Nawata; K Kurasawa; K Takabayashi; S Miike; N Watanabe; M Hiraguri; Y Kita; M Kawai; Y Saito; I Iwamoto
Journal:  J Rheumatol       Date:  1999-07       Impact factor: 4.666

5.  Clinical features and prognosis of patients with idiopathic inflammatory myopathies and anti-Jo-1 antibodies.

Authors:  Pawel Mielnik; Ewa Wiesik-Szewczyk; Marzena Olesinska; Hanna Chwalinska-Sadowska; Jakub Zabek
Journal:  Autoimmunity       Date:  2006-05       Impact factor: 2.815

6.  Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis.

Authors:  E H Kang; E B Lee; K C Shin; C H Im; D H Chung; S K Han; Y W Song
Journal:  Rheumatology (Oxford)       Date:  2005-06-21       Impact factor: 7.580

7.  Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis.

Authors:  T Yoshida; H Koga; F Saitoh; M Sakamoto; M Harada; H Yoshida; S Sakisaka; M Sata
Journal:  Intern Med       Date:  1999-09       Impact factor: 1.271

8.  Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy.

Authors:  Kerry B Stone; Chester V Oddis; Noreen Fertig; Yasuhiro Katsumata; Mary Lucas; Molly Vogt; Robyn Domsic; Dana P Ascherman
Journal:  Arthritis Rheum       Date:  2007-09

9.  Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases.

Authors:  Katalin Dankó; Andrea Ponyi; Tamás Constantin; Gábor Borgulya; Gyula Szegedi
Journal:  Medicine (Baltimore)       Date:  2004-01       Impact factor: 1.889

10.  Interstitial lung disease in polymyositis and dermatomyositis.

Authors:  I Marie; E Hachulla; P Chérin; S Dominique; P-Y Hatron; M-F Hellot; B Devulder; S Herson; H Levesque; H Courtois
Journal:  Arthritis Rheum       Date:  2002-12-15
View more
  34 in total

1.  Pulmonary manifestations of systemic autoimmune diseases.

Authors:  Manole Cojocaru; Inimioara Mihaela Cojocaru; Isabela Silosi; Camelia Doina Vrabie
Journal:  Maedica (Bucur)       Date:  2011-07

2.  Interstitial Lung Disease in Idiopathic Inflammatory Myopathy.

Authors:  Lesley Ann Saketkoo; Dana P Ascherman; Vincent Cottin; Lisa Christopher-Stine; Sonye K Danoff; Chester V Oddis
Journal:  Curr Rheumatol Rev       Date:  2010-05

3.  Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease.

Authors:  Julio A Huapaya; Leann Silhan; Iago Pinal-Fernandez; Maria Casal-Dominguez; Cheilonda Johnson; Jemima Albayda; Julie J Paik; Abanti Sanyal; Andrew L Mammen; Lisa Christopher-Stine; Sonye K Danoff
Journal:  Chest       Date:  2019-06-22       Impact factor: 9.410

Review 4.  Management of interstitial lung disease associated with connective tissue disease.

Authors:  Stephen C Mathai; Sonye K Danoff
Journal:  BMJ       Date:  2016-02-24

Review 5.  Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

Authors:  Tsuneyo Mimori; Ran Nakashima; Yuji Hosono
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

6.  Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases.

Authors:  Kuang-Hui Yu; Yeong-Jian Jan Wu; Chang-Fu Kuo; Lai-Chu See; Yu-Ming Shen; Hsiao-Chun Chang; Shue-Fen Luo; Huei-Huang Ho; I-Jung Chen
Journal:  Clin Rheumatol       Date:  2011-09-14       Impact factor: 2.980

7.  Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain.

Authors:  Laura Nuño-Nuño; Beatriz Esther Joven; Patricia E Carreira; Valentina Maldonado-Romero; Carmen Larena-Grijalba; Irene Llorente Cubas; Eva Gloria Tomero; María Carmen Barbadillo-Mateos; Paloma García De la Peña Lefebvre; Lucía Ruiz-Gutiérrez; Juan Carlos López-Robledillo; Henry Moruno-Cruz; Ana Pérez; Tatiana Cobo-Ibáñez; Raquel Almodóvar González; Leticia Lojo; María Jesús García De Yébenes; Francisco Javier López-Longo
Journal:  Rheumatol Int       Date:  2017-09-02       Impact factor: 2.631

8.  Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis.

Authors:  Yoshinao Muro; Kazumitsu Sugiura; Masashi Akiyama
Journal:  Clin Rheumatol       Date:  2012-12-19       Impact factor: 2.980

Review 9.  Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management.

Authors:  Flavia V Castelino; John Varga
Journal:  Arthritis Res Ther       Date:  2010-08-23       Impact factor: 5.156

10.  Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease.

Authors:  Dong Jin Go; Jin Kyun Park; Eun Ha Kang; Hyun Mi Kwon; Yun Jong Lee; Yeong Wook Song; Eun Bong Lee
Journal:  Rheumatol Int       Date:  2015-07-30       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.